Headquartered in Rahway, NJ Fiscal year ends December NYSE: MRK merck.com
Merck & Co., Inc. (known as MSD outside the United States and Canada) is a global research-intensive biopharmaceutical company that discovers, develops, manufactures, and markets medicines, vaccines, and animal health products. Its pharmaceutical portfolio is anchored by KEYTRUDA (pembrolizumab), a blockbuster PD-1 immunotherapy used across numerous cancer indications, now complemented by the subcutaneous formulation KEYTRUDA QLEX. The company's oncology pipeline spans antibody-drug conjugates (sacituzumab tirumotecan), KRAS inhibitors (calderasib), and personalized cancer vaccines (with Moderna). Beyond oncology, Merck markets WINREVAIR for pulmonary arterial hypertension, GARDASIL 9 for HPV prevention, BRIDION for neuromuscular blockade reversal, and recently launched LIPFENDRA, the first oral daily PCSK9 inhibitor for cholesterol management. The company is advancing tulisokibart in immunology, islatravir-based regimens in HIV, and CAPVAXIVE in pneumococcal disease. Its Animal Health segment sells livestock and companion animal products globally, including the BRAVECTO parasiticide line. Merck generates revenue across the United States, Europe, Asia Pacific, Japan, China, Latin America, and other markets worldwide. Updated
Defense and big pharma own the top of the board at the open, led by Northrop Grumman up 5.36%, with Eli Lilly, Bristol-Myers Squibb and Merck also higher. The pain is concentrated in crypto miners and optics names, where IREN leads the decline.
Cramer wants to add software as the bounce-back trade and the beaten-down industrial names tied to data center power. He also warns that rising rates are the real threat heading into earnings season in a couple of weeks.
Salazar rotated out of insurance and legacy tech and into big pharma, with two Merck buys of up to $50,000 each landing the same August day she sold Chubb. The filing also shows private SpaceX shares bought in two separate accounts, a reminder that members are accessing pre-IPO names retail investors cannot touch. Disclosed 33 days after the trades.
When a drugmaker's top product loses patent protection, the dividend usually takes the hit. Four pharma giants are each betting on newer drugs to fill the gap, but how close each one…
Full late-stage results for the personalized melanoma vaccine from Moderna (NASDAQ:MRNA | MRNA Price Prediction) and Merck (NYSE:MRK) came back positive, yet the selling hasn’t stopped. Those numbers landed short of the…
A late-stage melanoma vaccine report that was posted online and quickly pulled is driving a violent repricing in Moderna (NASDAQ:MRNA | MRNA Price Prediction) shares, even though its findings looked favorable on…
Pfizer's 5.7% dividend yield towers over Merck's, yet that gap may signal something retirees cannot afford to ignore. Before you chase the bigger payout, the coverage numbers behind each dividend tell a…
Johnson and Johnson just posted a quarter where one business charged ahead while another quietly stalled, and which side wins out will determine whether the stock earns its premium valuation over rivals…
Moderna‘s (NASDAQ:MRNA | MRNA Price Prediction) push into cancer treatment is drawing heavy buying as a closely followed melanoma presentation approaches. Shares of Moderna are up 7% to $241.89 during the trading…
Pfizer's 5.8% yield looks tempting until you check what the dividend is actually costing the company relative to its cash generation. The math behind that payout is more uncomfortable than the headline…
Johnson & Johnson just posted a quarter that sent shares sliding despite a headline beat, yet analysts keep piling into the bull camp with price targets well above current levels. Here is…
Bristol Myers Squibb has raised its dividend for 17 straight years, but a looming patent cliff and $43 billion in debt put the pace of future increases on a collision course with…
Profit taking is hitting one of biotech’s hottest trades, and the selling is landing heaviest on the stock that ran the furthest. Moderna (NASDAQ:MRNA | MRNA Price Prediction) stock is down 10%…
When tech stocks crack, most investors discover too late that their portfolios were far more concentrated than they realized. Jim Cramer and others are pointing to a handful of quiet winners that…
Amgen and Merck both yield around 2.3% and have surged this year, but one of them is paying its dividend out of thin air while the other has a cash cushion that…
Moderna has surged more than 650% this year on cancer vaccine excitement, but analyst targets sit far below the current share price. Before you chase the rally, there are some uncomfortable numbers…
Retirees watching CD rates scrape bottom and Treasury coupons lock in for a decade have a third option hiding in plain sight inside the Dow Jones Industrial Average, and it requires owning…
Skyrizi and Rinvoq are growing fast, a blockbuster acquisition just closed, and the FDA handed AbbVie a fresh approval, yet the stock sits just shy of a price target that has Wall…
Merck & Co., Inc. (known as MSD outside the United States and Canada) is a global research-intensive biopharmaceutical company that discovers, develops, manufactures, and markets medicines, vaccines, and animal health products.
24/7 Wall St.'s 12-month price target for MRK is $129.23, rated Hold. The Wall Street consensus target is $159.76. MRK price prediction →
